GTX (GTXI) Reports Two POWER Trials Failed to Meet co-Primary Endpoints
Tweet Send to a Friend
GTX, Inc. (Nasdaq: GTXI) announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
